Repatha (evolocumab) is a brand-name subcutaneous injection that isn’t known to interact with alcohol, other drugs, or supplements. However, Repatha has health-related interactions that are ...

The company’s Repatha (evolocumab) was added to optimised statin therapy in a phase 3 trial, and resulted in statistically significant regression of atherosclerosis in patients with coronary ...

Repatha (evolocumab) will be sold in the UK at a cost of $6,780 per year, less than half the $14,100 Amgen is charging for the drug in the US, with the price in other EU markets typically below ...

Notable contributors included Repatha (evolocumab) for hypercholesterolemia and hyperlipidemia, Blincyto (blinatumomab) for B-cell acute lymphocytic leukaemia, recently approved in June 2024, and ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Notable contributors included Repatha (evolocumab) for hypercholesterolemia and hyperlipidemia, Blincyto (blinatumomab) for B-cell acute lymphocytic leukaemia, recently approved in June 2024 ...

Nexletol and Repatha are both cholesterol-lowering medications. Repatha contains the active ingredient evolocumab. Nexletol’s active ingredient is bempedoic acid. Repatha works in a slightly ...

Verve Therapeutics saw its stock surge by more than 26% when markets opened today (14 April) after the company announced early-stage clinical data for its Eli Lilly-partnered experimental gene ...